---

---

positive   symbols : Sny   

save search

---

Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K |

Health Technology

| 1.5% | O: -0.4% H: 3.01% C: 2.94%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| 3.25% | O: 0.83% H: 1.35% C: 1.2%
ABT | News | $106.89 -0.65% -0.22% 5.1M |

Health Technology

| 1.12% | O: -0.75% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 3.41% | O: 0.82% H: 0.0% C: 0.0%
first treatment for

---

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 0.13% | O: 1.17% H: 0.0% C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K |

Health Technology

| -2.65% | O: -0.73% H: 1.52% C: 0.5%
positive blood care topline results study

---

AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 08:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 0.13% | O: 1.17% H: 0.0% C: 0.0%
lung drug cancer treatment application therapeutics

---

Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 0.13% | O: 1.17% H: 0.0% C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M |

Health Technology

| -13.51% | O: 0.4% H: 0.38% C: -1.77%
lung cancer treatment therapeutics china

---

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
MLTX | $42.45 -1.85% -1.88% 220K |

| -16.91% | O: 0.0% H: 2.86% C: 0.13%
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -3.08% | O: -0.82% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -2.73% | O: 0.89% H: 0.0% C: 0.0%
nanobody fda positive ema program

---

Achondroplasia Treatment Drug Market to Register Positive Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Ascendis Pharma, QED Therapeutics (BridgeBio), Novartis, Sanofi, RIBOMIC
Published: 2024-01-09 (Crawled : 22:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -9.34% | O: 0.13% H: 0.0% C: 0.0%
drug companies achondroplasia positive treatment key therapeutics growth market

---

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
Published: 2023-12-15 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -2.57% | O: -0.93% H: 0.0% C: 0.0%
first positive treatment ema africa

---

Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published: 2023-12-13 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -1.74% | O: 0.25% H: 0.0% C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 26.72% | O: 1.8% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -2.57% | O: 0.0% H: 0.0% C: 0.0%
positive cancer growth study market

---

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda
Published: 2023-12-12 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| 0.52% | O: -0.06% H: 2.36% C: 2.36%
UCBJY | $65.26 -4.38% 5.9K |

Manufacturing

| 55.94% | O: -0.62% H: 1.01% C: 1.01%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -3.35% | O: -0.71% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -0.74% | O: -0.27% H: 2.28% C: 2.16%
CPRX | News | $15.12 2.65% 2.58% 940K |

Health Technology

| 10.34% | O: -0.37% H: 5.49% C: 5.49%
companies positive growth study market

---

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
Published: 2023-12-07 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| 2.32% | O: -1.66% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 1.71% | O: -1.19% H: 0.0% C: 0.0%
positive ongoing collaboration study

---

Metastatic HER2-Positive Breast Cancer Market to Grow by 2032 at a 5.2% CAGR | DelveInsight
Published: 2023-11-29 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| 1.25% | O: -0.35% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 0.99% | O: -1.09% H: 0.0% C: 0.0%
IMMP | $2.59 3.19% 3.09% 1.4M |

Health Technology

| 30.73% | O: 3.13% H: 1.52% C: 0.51%
breast cancer market

---

Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD
Published: 2023-11-27 (Crawled : 17:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -1.0% | O: -0.36% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -0.11% | O: 1.04% H: 0.17% C: 0.11%
dupixent positive copd results sanofi

---

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -1.0% | O: -0.36% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -0.11% | O: 1.04% H: 0.17% C: 0.11%
REGN | News | $906.55 -0.09% -0.08% 370K |

Health Technology

| 13.66% | O: 0.46% H: 0.37% C: -0.49%
dupixent fda disease approved positive copd potential submission

---

Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -1.0% | O: -0.36% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -0.11% | O: 1.04% H: 0.17% C: 0.11%
REGN | News | $906.55 -0.09% -0.08% 370K |

Health Technology

| 13.66% | O: 0.46% H: 0.37% C: -0.49%
dupixent fda disease approved positive copd potential submission

---

Generalized Anxiety Disorder Treatment Market to Showcase Positive Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Players - MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics
Published: 2023-10-30 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| 6.51% | O: 4.66% H: 0.0% C: -3.51%
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -24.44% | O: -1.67% H: 3.16% C: 2.75%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 5.99% | O: 2.61% H: 0.0% C: 0.0%
positive treatment growth market

---

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M |

Health Technology

| -14.35% | O: -0.39% H: 2.48% C: 1.8%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -11.36% | O: 0.09% H: 0.0% C: 0.0%
BNTX | News | $88.18 -0.35% -0.35% 280K |

Health Technology

| -7.1% | O: 0.99% H: 1.81% C: 0.47%
covid-19 vaccine positive influenza topline program

---

Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-10-25 (Crawled : 19:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -8.94% | O: 0.4% H: 1.29% C: 1.29%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -10.17% | O: 1.43% H: 0.64% C: -0.09%
ALNY | $143.8 -1.55% -1.58% 390K |

Health Technology

| -10.91% | O: -1.28% H: 0.58% C: -1.46%
disease alzheimer’s positive results

---

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 15:30) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -8.72% | O: 0.73% H: 0.0% C: -0.48%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -10.11% | O: -0.69% H: 0.0% C: 0.0%
BNTX | News | $88.18 -0.35% -0.35% 280K |

Health Technology

| -2.66% | O: -2.24% H: 7.12% C: 4.11%
bnt211 candidate congress tumors positive update cell car-t therapy

---

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
Published: 2023-10-11 (Crawled : 14:00) - globenewswire.com
MLTX | $42.45 -1.85% -1.88% 220K |

| -26.76% | O: 1.63% H: 1.95% C: -8.55%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -13.25% | O: 1.1% H: 0.0% C: 0.0%
nanobody congress positive trial

---

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
Published: 2023-10-04 (Crawled : 12:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -11.71% | O: 1.07% H: 0.0% C: 0.0%
MRNA | News S | $108.82 0.86% 0.85% 3.4M |

Health Technology

| 4.67% | O: 1.48% H: 0.2% C: -0.33%
rna-1083 covid-19 vaccine positive influenza

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---